Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT9HKJA)

• DTT Name: Vascular endothelial growth factor (VEGF)
• Synonyms: Vascular endothelial cell growth factor
• Gene Name: VEGF
• DTT Type: Successful target; [1]
• BioChemical Class: Growth factor
• UniProt ID: VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN
• TTD ID: T96721
• KEGG Pathway:
  EGFR tyrosine kinase inhibitor resistance (hsa01521)
  MAPK signaling pathway (hsa04010)
  Ras signaling pathway (hsa04014)
  Rap1 signaling pathway (hsa04015)
  Calcium signaling pathway (hsa04020)
  HIF-1 signaling pathway (hsa04066)
  PI3K-Akt signaling pathway (hsa04151)
  VEGF signaling pathway (hsa04370)
  Focal adhesion (hsa04510)
  Relaxin signaling pathway (hsa04926)
  AGE-RAGE signaling pathway in diabetic complications (hsa04933)
  Human cytomegalovirus infection (hsa05163)
  Human papillomavirus infection (hsa05165)
  Kaposi sarcoma-associated herpesvirus infection (hsa05167)
  Pathways in cancer (hsa05200)
  Proteoglycans in cancer (hsa05205)
  MicroRNAs in cancer (hsa05206)
  Chemical carcinogenesis - receptor activation (hsa05207)
  Chemical carcinogenesis - reactive oxygen species (hsa05208)
  Renal cell carcinoma (hsa05211)
  Pancreatic cancer (hsa05212)
  Bladder cancer (hsa05219)
  Rheumatoid arthritis (hsa05323)
  Fluid shear stress and atherosclerosis (hsa05418)
• Reactome Pathway:
  Regulation of gene expression by Hypoxia-inducible Factor (R-HSA-1234158)
  Signaling by VEGF (R-HSA-194138)
  VEGF ligand-receptor interactions (R-HSA-194313)
  VEGF binds to VEGFR leading to receptor dimerization (R-HSA-195399)
  VEGFA-VEGFR2 Pathway (R-HSA-4420097)
  VEGFR2 mediated cell proliferation (R-HSA-5218921)
  Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)
  TFAP2 (AP-2) family regulates transcription of growth factors and their receptors (R-HSA-8866910)
  Potential therapeutics for SARS (R-HSA-9679191)
  Platelet degranulation (R-HSA-114608)

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[2]

19 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[4]
M710	DM1PRT6	Diabetic macular edema	9B71.02	Phase 3	[5]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[6]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[8]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[10]
ALG-1001	DMR2YPF	Diabetic macular edema	9B71.02	Phase 2	[11]
AVA-101	DMASRP3	Age-related macular degeneration	9B75.0	Phase 2	[12]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
TG100801	DMPH1AG	Macular degeneration	9B78.3	Phase 2	[14]
ABT-165	DMQ3O1U	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[16]
BI-836880	DMGFH7T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
NM-3	DM5INE7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
NOV1501	DME2QUZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
PAN-90806	DMY9LG1	Diabetic retinopathy	9B71.0	Phase 1	[20]
Zifibancimig	DMIJ2MZ	Neovascular age-related macular degeneration	9B78.3Z	Phase 1	[21]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[22]

References

• [1] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [2] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [3] Clinical pipeline report, company report or official report of Fujifilm.
• [4] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [5] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [6] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [7] National Cancer Institute Drug Dictionary (drug id 43234).
• [8] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
• [9] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [10] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [11] Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
• [12] Clinical pipeline report, company report or official report of Avalanche Biotechnologies.
• [13] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [14] Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42.
• [19] Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Clinical pipeline report, company report or official report of Roche
• [22] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.